ESMO 2021: How Does 6 Months of Trastuzumab Measure Up to Longer Treatment in Early Breast Cancer?
Posted: Tuesday, September 21, 2021
Adjuvant treatment with 6 months of trastuzumab appears to be noninferior to 12 months of treatment—the current standard of care—in women with HER2-positive early breast cancer; however, noninferiority was not confirmed for patients treated with 9 weeks of trastuzumab. These were the findings of a meta-analysis conducted by Helena M. Earl, MBBS, PhD, of the University of Cambridge, England, and colleagues, which were presented during the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract LBA11).
This individual patient data meta-analysis included five noninferiority randomized controlled trials; the PERSEPHONE, PHARE, and HORG studies compared 12 months with 6 months of treatment with trastuzumab, and the SOLD and Short-HER trials compared 12 months with 9 weeks of trastuzumab. In all, approximately 11,500 patients treated with trastuzumab were included in the analysis.
For 12 months of treatment compared with a shorter course of treatment, the 5-year invasive disease–free survival rates were 88.46% and 86.87%, respectively. For 12 months versus 6 months, the 5-year invasive disease–free survival rates were 89.26% and 88.56%, respectively, and the adjusted hazard ratio for treatment was 1.07 (noninferiority P = .02). For 12 months versus 9 weeks, the 5-year invasive disease–free survival rates were 91.40% and 89.22%, respectively; the adjusted hazard ratio for treatment was 1.27 (noninferiority P = .56).
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.
